Since April 2021, increased cases of myocarditis and pericarditis have been reported in the United States after mRNA COVID-19 vaccination ( Pfizer-BioNTech and Moderna ), particularly in adolescents and young adults.
There has not been a similar reporting pattern observed after receipt of the Janssen COVID-19 Vaccine ( Johnson & Johnson ).
In most cases, patients who presented for medical care have responded well to medications and rest and had prompt improvement of symptoms.
Reported cases have occurred predominantly in male adolescents and young adults 16 years of age and older.
Onset was typically within several days after mRNA COVID-19 vaccination, and cases have occurred more often after the second dose than the first dose.
CDC and its partners are investigating these reports of myocarditis and pericarditis following mRNA COVID-19 vaccination.
CDC continues to recommend COVID-19 vaccination for everyone 12 years of age and older given the risk of COVID-19 illness and related, possibly severe complications, such as long-term health problems, hospitalization, and even death.
Myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the lining outside the heart. In both cases, the body’s immune system is causing inflammation in response to an infection or some other trigger. Symptoms can include chest pain, shortness of breath, or palpitations.
The severity of cases of myocarditis and pericarditis can vary. For the cases reported after mRNA COVID-19 vaccination, most who presented to medical care have responded well to medications and rest.
Recommendations for clinicians
CDC continues to recommend COVID-19 vaccination for everyone 12 years of age and older given the greater risk of other serious complications related to COVID-19, such as hospitalization, multisystem inflammatory syndrome in children ( MIS-C ), or death.
a) Report all cases of myocarditis and pericarditis post COVID-19 vaccination to VAERS;
b) Consider myocarditis and pericarditis in adolescents or young adults with acute chest pain, shortness of breath, or palpitations. In this younger population, coronary events are less likely to be a source of these symptoms;
c) For initial evaluation, consider an ECG, troponin level, and inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate. In the setting of normal ECG, troponin, and inflammatory markers, myocarditis or pericarditis are unlikely;
d) For suspected cases, consider consultation with cardiology for assistance with cardiac evaluation and management. Evaluation and management may vary depending on the patient age, clinical presentation, potential causes, or practice preference of the provider. ( Xagena )
Source: CDC ( U.S. Centers for Disease Control and Prevention ), 2021